Trial Profile
Safety and pharmacokinetic study of ponatinib in patients with chronic hepatic impairment and matched healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Dec 2015
Price :
$35
*
At a glance
- Drugs Ponatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors ARIAD Pharmaceuticals
- 05 Dec 2015 New trial record